Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.

Abstract: The present invention relates to an industrially advantageous process of making bisphosphonic acid or its salt in particular risedronic acid, [1-hydroxy-2(3-pyridinyl)ethylidene]bisphosphonic acid, having formula-(I) or its salts in high purity and high yields.

Abstract: A composition comprising Chinese herbal medicines Ramulus cinnamomi and Poria cocos is provided, wherein the composition is defined by a fingerprint profile obtained from an improved chromatographic method. Various uses of such compositions are also provided.

Abstract: This invention provides a high-purity, high-concentrated silica sol with long-term stability and low viscosity by preventing viscosity-increase after production, and method for producing the same. In one embodiment, the silica sol produced by an alkoxide method comprises at least a dispersing agent and silica, wherein the concentration of said dispersing agent is 10-3000 ppm with respect to the silica, wherein said dispersing agent may be an inorganic acid, inorganic acid salt, organic acid or organic acid salt whose degradation temperature and boiling point are both 60° C. or higher, wherein said silica sol has a silica concentration of 20% weight or higher.

Abstract: The invention consists in a nucleotide sequence having the size of (2646) bp, wherein the order of nucleotides is identical to the order of the nucleotide sequence encoding penicillin acylase from Achromobacter sp. CCM 4824 (formerly Comamonas testosteroni CCM 4824), eventually of the fragments of this sequence having the length of at least 150 nucleotides. The sequence can be used in the formation of a DNA construct, eventually the construct having at least one regulatory sequence regulating the expression of the gene and the production of a polypeptide with the penicillin acylase activity. The sequence can form part of a recombinant expression vector, which consists of the above-mentioned construct, promoter, translational start signal, translational and transcriptional stop signal. Further, the invention concerns a recombinant host cell, containing the nucleic acid construct carried by the vector or integrated into the cell chromosome, and the E.

Abstract: The present invention provides a device for cleaning tubes, in particular the internal surfaces of tubes in heat exchange systems. The device comprises a mass (2) with an optionally provided central through-hole (10) disposed thereon, and optionally provided a plurality of protrusions (20, 21) mounted and/or moulded on the mass (2). The through-hole (10) is preferably of a conical shape-like configuration. A plurality of first protrusions (20) is disposed in a fin-like arrangement on the mass (2). A plurality of second protrusions (21) is disposed in a spiral arrangement on the mass (2), and the lengths of the second protrusions (21) are relatively longer than the length of the first protrusions (20). The mass may consist of an asymmetrically positioned weighted core (15) of different weights and sizes to provide a variety of relative density to the device and to serve as a geometrical manipulation to impart rotational momentum and random dynamic motion to the device.

Abstract: The present invention relates to the preparation and pharmacological use of sinomenine derivatives of formula I. The approach disclosed herein is the modification of D ring by-substituting for R. Additional substitutions in the other rings are also provided herein. Several of the sinomenine derivatives have significantly greater anti-inflammation activity when compared with the parent compound.

Abstract: A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating cancer in a mammal is also disclosed. The method comprises administering a suitable orally administered glucan and at least one antibody for the treatment of cancer to the mammal. In addition a composition for delivery of peptide, protein, RNA, DNA or plasmid comprising effective amount of a beta-glucan is disclosed.

Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.

Abstract: A consumable packaging composition is provided for packaging clear-binders, made of one or several packaging materials, alone or in combination, such as plastics, polymers and extenders, and which melting point is adjusted so that the packaging material melts when in contact with the hot aggregates as methods of using them, are also disclosed. Optionally, and prior to packaging, the clear-binder may be mixed together with one or several color pigments used for production of colored mixes depending on the end-user requirements. In a preferred practice, the size of the packaged clear-binder product containers is adjusted such that, after transport and storage, the packaged material together with the packaging material can be directly incorporated along any of the steps of a production process that uses clear-binders. The packaged clear-binder material permits handling and manipulation to be reduced to the minimum necessary, thus avoiding the need for pre-heating and hot-storage of clear-binders.

Abstract: This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.

Abstract: The present invention discloses the use of Allele-Specific-Oligonucleotide (ASO) as a detection assay for human HLA classification. Using Reversed-Dot-Blotting format and flow through hybridization process, more efficient, faster and less expensive HLA classification can be achieved. A simplified procedure for HLA genotyping is also described. This invention further provides a Single Nucleotide Polymorphism (SNP)-based DNA fingerprining method for rapid and accurate genotyping, identification as well as DNA analyses of genetic data from human beings and different organisms. In addition this invention also discloses a new device for rapid and sensitive analyses of nucleic acids, proteins and other analysts for diagnosis.

Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.

Abstract: This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder.

Abstract: Anti-idiotypic antibodies which recognise the idiotope of an antibody specific for a yeast killer toxin possess microbicidal activity. Fragments (e.g. decapeptides) of these anti-idiotypic antibodies, particularly those comprising CDR residues, also show microbicidal activity, as do peptides having 5 the same sequence but composed of D-amino acids, or including amino acid substitutions. Peptidomimetics of these microbicidal polypeptides are also provided. Antiviral activity is also seen.

Abstract: This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance, which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.

Abstract: This invention provides a method for identifying a composition of Cinnamomi and Poria. This invention further provides a composition comprising: Ramulus Cinnamomi, Poria Cortex, Moutan Radicis, Radix Paeonize Alba, and Semen Persicae. This invention provides various uses of these compositions.

Abstract: A mobile containerized autopsy facility for use in distant contamination zones, comprising at least one enclosure which includes at least one seamless and sealable compartment, which compartment meets biohazard safety level 3 and 4 requirements. The facility consists of enclosures that are most commonly a conversion of at least one standard 40×8×9.5 foot refrigerated cargo container that may be easily transported by trailers or by air to remote sites and be operational without the dependence on local infrastructure.

Abstract: A method is described by which stem cells are induced to differentiate into cardiomycocytes; the method comprises exposure for a length of time and at efficacious quantities of a protein of the EGF-CFC family or its derivatives having at least the EGE and CFC domains; or to differentiate into neuronal cells, comprising the exposure to Cripto protein inhibitors. Compositions are described for therapeutic use in treating heart disorders, comprising a therapeutically efficacious quantity of a protein or its derivatives having at least the EGF and CFC domains of a protein of the EGF-CFC family.

Abstract: A process for preparation of rabeprazole sodium comprising oxidation of wet or dry rabeprazole sulphide with sodium hypohalite in water or a mixture of water and water miscible solvent using alkali metal hydroxide and catalyst is disclosed herein. The present invention also discloses process for preparation of rabeprazole sulphide.